secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2026-06-03T10:01:45+00:00
Accession:  0001193125-26-254476
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC
--------------------------------------------------------------------------------

- IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.
- IDEAYA will sponsor the Phase 1 combination trial; Roche will supply RG6505.
- MTAP deletion occurs in up to 40% of PDAC; almost all such cases have co-occurring RAS mutations.
- Both companies retain full commercial rights to their compounds; joint governance oversees the study.
- Triplet combination with IDE397 (MAT2A inhibitor) may be evaluated with joint approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/0001193125-26-254476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/d53214d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer